[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mortality-rate\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mortality-rate":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100327753","phase-4-rectal-indomethacin-as-early-treatment-for-acute-pancreatitis-indomap-trial-100327753",false,"NCT03547232","Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial)","Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial): Study Protocol for a Multi-center, Double-blinded, Placebo-controlled, Randomized Clinical Trial","INDOMAP","Inclusion Criteria:\n\n* All patients ages 18-80 years with a diagnosis of AP based on at least 2 of the following criteria:\n* Abdominal pain characteristic of AP\n* Serum amylase and\u002For lipase ≥ 3 times the upper limit of normal\n* Characteristic findings of AP on abdominal CT scan will be screened for study enrollment.\n\nExclusion Criteria:\n\n* Onset time \\>24 hours\n* Presence of renal dysfunction (serum creatinine \\> 1.5 \\*normal upper limit)\n* Severe liver dysfunction\n* Active peptic ulcer disease or GI bleeding\n* Pregnancy or breast-feeding\n* Hypersensitivity to NSAIDs\n* New-onset, exacerbation or uncontrolled hypertension\n* Presence of serious cardiovascular events, including severe heart failure, myocardial infarction (MI) and stroke\n* Mental disability\n* Malignancy-associated acute pancreatitis\n* Post-ERCP pancreatitis\n* Informed consent not signed","ALL","18 Years","80 Years",{"count":21,"type":22},1504,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Acute pancreatitis (AP) is an inflammatory condition of the pancreas following the activated pancreatic enzymes induced by varied causes, with or without other organ(s) dysfunction. The production and release of inflammatory factors is generally considered as the key factor of pathogenesis. Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly applied agents for inflammatory diseases. A series studies have proved that indomethacin can reduce the risk of post-endoscopic retrograde cholangiopancreatography (ERCP), but high-quality evidence is still lacking in the field of effectiveness of NSAIDs to treat, rather than prevent, other types of AP. Majority of animal experiments showed that NSAIDs had protective effects for organ functions, but the results of several preliminary clinical studies were inconsistent. Randomized controlled trials are eagerly awaited to elucidate its effects on AP.",[28,29,30,31],"Acute Pancreatitis","Complication","Mortality Rate","Organ Failure, Multiple",[33,34,35,36],"Acute pancreatitis","Indomethacin","Prognosis","Organ dysfunction","RECRUITING","2025-06-11",{"date":40,"type":41},"2025-06-15","ACTUAL",{"date":43,"type":41},"2024-12-01",{"date":45,"type":22},"2028-12-01",{"name":47,"class":48},"Peking Union Medical College Hospital","OTHER",17,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100550466","clinical-outcomes-of-mega-dosage-supplementations-of-cholecalciferol-in-critically-ill-patients-with-sepsis-100550466","NCT06447441","Clinical Outcomes Of Mega-dosage Supplementations Of Cholecalciferol In Critically Ill Patients With Sepsis","MDC-S","Inclusion Criteria:\n\n1. Medical subject ≥ 18 years old and diagnosed with sepsis\n2. Transferred to the intensive care unit within 24 hours after being diagnosed with sepsis\n3. Admitted to the ICU with 40 \\> APACHE II score ≥ 15.\n4. The intensivist anticipates that the subject will stay in the ICU ≥ 7 days.\n\nExclusion Criteria:\n\n1. Diseases that affect serum levels of 25(OH)D and calcium, including thyroidectomy, parathyroid disease, rickets, or severe cirrhosis \\[Child C\\]\n2. Received large doses of vitamin D3 in the past four weeks (\\> 2000 IU per day or ≥ 10,000 IU in a single dose)\n3. Admitted to the ICU with diagnosis of COVID-19\n4. AIDS subjects taking immunosuppressants\n5. Organ transplant\n6. Active cancer\n7. Tuberculosis, sarcoidosis, or kidney stones in the past one year\n8. Weight \\\u003C 45 kg or \\> 90 kg\n9. Had been admitted to ICU in the past three months\n10. Subject and family members who do not speak the native language\n11. Pregnant women","100 Years",{"count":59,"type":22},240,[61],"NA","Non-COVID-19 sepsis (Sepsis) has always been one of the common diseases in critically ill patients. The main treatment strategy is to kill pathogens and mitigate hyperinflammation. One study demonstrated that the supplementation with 576,000 IU cholecalciferol (vitamin D3) as a single dose in critically ill adults in the medical intensive care units (MICUs) can improve clinical outcomes, including acute physiology and chronic health evaluation II score (APACHE II), sequential organ failure assessment score (SOFA), and C-reactive protein (CRP).\n\nIt is a three-year, multi-center, prospective, parallel, double-blind, randomized controlled clinical trial for 240 eligible subjects, with administrations of vitamin D3 576,000 IU or placebo every 24 hours for 3 days (72 hours) within 96 hours after intensive care unit (ICU) admission.",[64,65,30,66],"Critically Ill","Sepsis","Critical Care",[68,69,65],"Vitamin D","Cholecalciferol","NOT_YET_RECRUITING","2024-06-14",{"date":73,"type":41},"2024-06-17",{"date":75,"type":22},"2024-07-01",{"date":77,"type":22},"2029-12-31",{"name":79,"class":48},"Chimei Medical Center"]